title: Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial.
abstract: OBJECTIVE
  We assessed the predictive value of minimum stent area (MSA) for long-term patency of sirolimus-eluting stents (SES) implantation compared to bare metal stents (BMS).
  
  
  BACKGROUND
  Although MSA is a consistent predictor of in-stent restenosis, its predictive value in BMS is still limited because of biologic variability in the restenosis process.
  
  
  METHODS
  From the SIRolImUS (SIRIUS) trial, 122 cases (SES: 72; BMS: 50) with complete serial intravascular ultrasound (IVUS) (baseline and 8-month follow-up) were analyzed. Postprocedure MSA and follow-up minimum lumen area (MLA) were obtained. Based on previous physiologic studies, adequate stent patency at follow-up was defined as MLA >4 mm(2).
  
  
  RESULTS
  In both groups, a significant positive correlation was observed between baseline MSA and follow-up MLA (SES: p < 0.0001, BMS: p < 0.0001). However, SES showed higher correlation than BMS (0.8 vs. 0.65) with a higher regression coefficient (0.92 vs. 0.59). The sensitivity and specificity curves identified different optimal thresholds of MSA to predict adequate follow-up MLA: 5 mm(2) for SES and 6.5 mm(2) for BMS. The positive predictive values with these cutoff points were 90% and 56%, respectively.
  
  
  CONCLUSIONS
  In this SIRIUS IVUS substudy, SES reduced both biologic variability and restenosis, resulting in increased predictability of long-term stent patency with postprocedure MSA. In addition, SES had a considerably lower optimal MSA threshold compared to BMS.
authors.affiliation: Center for Research in Cardiovascular Interventions, Stanford University Medical Center, Stanford, California 94305-5637, USA.
authors.forename: Shinjo
authors.initials: S
authors.lastname: Sonoda
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Morino
authors.forename: Junya
authors.initials: J
authors.lastname: Ako
authors.forename: Mitsuyasu
authors.initials: M
authors.lastname: Terashima
authors.forename: Ali H M
authors.initials: AH
authors.lastname: Hassan
authors.forename: Heidi N
authors.initials: HN
authors.lastname: Bonneau
authors.forename: Martin B
authors.initials: MB
authors.lastname: Leon
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Moses
authors.forename: Paul G
authors.initials: PG
authors.lastname: Yock
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Honda
authors.forename: Richard E
authors.initials: RE
authors.lastname: Kuntz
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Fitzgerald
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D003324:Coronary Artery Disease / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D023903:Coronary Restenosis / Q000000981:diagnostic imaging*; D004311:Double-Blind Method; D004867:Equipment Design; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011237:Predictive Value of Tests; D012372:ROC Curve; D016032:Randomized Controlled Trials as Topic; D012680:Sensitivity and Specificity; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D016896:Treatment Outcome; D014463:Ultrasonography; D014481:United States
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus